New Insight on the Role of Plasminogen Receptor in Cancer Progression.

Cancer growth and metastasis Pub Date : 2015-07-29 eCollection Date: 2015-01-01 DOI:10.4137/CGM.S27335

Seema Kumari, Ramarao Malla

{"title":"New Insight on the Role of Plasminogen Receptor in Cancer Progression.","authors":"Seema Kumari, Ramarao Malla","doi":"10.4137/CGM.S27335","DOIUrl":null,"url":null,"abstract":"Objective: Plasminogen system plays a crucial role in physiological and pathological events related to tissue regeneration, wound healing, immune response, angiogenesis, invasion and metastasis. It gets activated when plasminogen associates with its cell surface receptors. Latest information on some of the well-explored plasminogen receptors such as annexin II-S100A10, cytokeratin 8, α-enolase, plasminogen receptor (KT) (Plg-R(KT)) and histone H2B has been discussed in the present review. These receptors can pave the way for effective new therapeutic and diagnostic strategies to counteract malignant diseases.Conclusion: The present review concludes the key role of plasminogen receptors in extracellular matrix degradation, infiltration into surrounding tissues, neovascularization, invasion, metastasis and drug resistance. This review also discusses the possible effect of blocking these plasminogen receptors with monoclonal antibodies and DNA-based vaccination or silencing plasminogen receptor gene using small interfering RNA or short hairpin RNA to counteract cancer invasion and metastasis.","PeriodicalId":88440,"journal":{"name":"Cancer growth and metastasis","volume":"8 ","pages":"35-42"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CGM.S27335","citationCount":"42","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer growth and metastasis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/CGM.S27335","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 42

Abstract

Objective: Plasminogen system plays a crucial role in physiological and pathological events related to tissue regeneration, wound healing, immune response, angiogenesis, invasion and metastasis. It gets activated when plasminogen associates with its cell surface receptors. Latest information on some of the well-explored plasminogen receptors such as annexin II-S100A10, cytokeratin 8, α-enolase, plasminogen receptor (KT) (Plg-R(KT)) and histone H2B has been discussed in the present review. These receptors can pave the way for effective new therapeutic and diagnostic strategies to counteract malignant diseases.

Conclusion: The present review concludes the key role of plasminogen receptors in extracellular matrix degradation, infiltration into surrounding tissues, neovascularization, invasion, metastasis and drug resistance. This review also discusses the possible effect of blocking these plasminogen receptors with monoclonal antibodies and DNA-based vaccination or silencing plasminogen receptor gene using small interfering RNA or short hairpin RNA to counteract cancer invasion and metastasis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纤溶酶原受体在癌症进展中的作用的新认识。

目的:纤溶酶原系统在组织再生、创面愈合、免疫应答、血管生成、侵袭转移等生理病理过程中发挥重要作用。当纤溶酶原与其细胞表面受体结合时，它就会被激活。本文综述了纤溶酶原受体如膜联蛋白II-S100A10、细胞角蛋白8、α-烯醇化酶、纤溶酶原受体(KT) (Plg-R(KT))和组蛋白H2B等的最新研究进展。这些受体可以为对抗恶性疾病的有效的新治疗和诊断策略铺平道路。结论:本文综述了纤溶酶原受体在细胞外基质降解、周围组织浸润、新生血管形成、侵袭转移和耐药等方面的关键作用。本文还讨论了用单克隆抗体和dna疫苗阻断这些纤溶酶原受体或用小干扰RNA或短发夹RNA沉默纤溶酶原受体基因来抑制肿瘤侵袭和转移的可能作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer growth and metastasis

自引率

0.00%

发文量

期刊最新文献

Apoptosis-Induced Compensatory Proliferation in Cancer Targeting Apoptosis to Overcome Chemotherapy Resistance Metastasis: Methods and Protocols CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche. The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules.